Private Market View

Galvanize Therapeutics

Therapeutic Devices · Redwood City, CA · Founded 2015 · Privately Held (backing)

PA Mark · $/share
$2
Sep 2026
Implied valuation
$300.0M
Total raised
$206.1M
Last round
Later Stage VC (Series C)
Jul 2025

Key facts

as of Sep 2026
  • Galvanize Therapeutics’s last known valuation is $300.0M (Mar 2022).
  • It has raised $206.1M across 4 recorded rounds; the latest was Later Stage VC (Series C) ($100.0M) in Jul 2025.
  • Notable investors include Fidelity Management & Research Company, Norwest, Sofinnova Partners, T. Rowe Price Group, Perceptive Advisors — 13 tracked in total.
  • 3 institutional filers report fund marks on Galvanize Therapeutics across 56 filings.
  • Galvanize Therapeutics has filed 5 Form Ds with the SEC since 2020, most recently Sep 2025 ($96.1M sold to 28 investors).
  • Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence
~$2per share
as of Sep 2026 · the exact daily mark is a member feature
Composed from 2 inputs:N-PORT marks 100%
See the platform prints behind this mark →
Free account
See the evidence behind this price
  • ·Post-money valuations for all 4 rounds
  • ·The complete investor list — 13 names
  • ·Watchlist + deal alerts for Galvanize Therapeutics
Create free account
No card required

Recorded secondary trades

No prints on record

No secondary trades in Galvanize Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

3 filers · latest Jun 2026

3 SEC-registered funds reported 56 fair-value marks on Galvanize Therapeutics between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 56 fund marks

Funding rounds

4 rounds
Jul 2025Later Stage VC (Series C)$100.0M▮
Mar 2022Later Stage VC (Series B)$100.0M▮
Feb 2022Debt$2.0MSEC filing▮
Mar 2020Early Stage VC$6.1MSEC filing▮
Full funding history →

About Galvanize Therapeutics

Developer of energy-based medical device technology designed to improve biological processes. The company's tool utilizes short-duration and high-voltage electrical pulses to create an electric field that destabilizes cells through multiple biochemical processes, enabling medical professionals to deliver improved healthcare services to patients.

Industry
Therapeutic Devices
Sector
Healthcare
HQ
Redwood City, CA, United States
Founded
2015
Employees
134
Ownership
Privately Held (backing)